Saitama Medical University · Faculty of Medicine / Graduate School of Medicine · 講師

Research keywordsnon-small cell lung cancer・durvalumab maintenance・nivolumab retreatment・pegylated G-CSF・immune-related adverse events・thoracic oncology

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer
• Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer
• 吸入ステロイドが著効した挿管後気管狭窄の1例
• Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab.

• Official profile